Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

نویسندگان

  • John J.V. McMurray
  • Inder S. Anand
  • Rafael Diaz
  • Aldo P. Maggioni
  • Christopher O'Connor
  • Marc A. Pfeffer
  • Scott D. Solomon
  • Michal Tendera
  • Dirk J. van Veldhuisen
  • Moetaz Albizem
  • Sunfa Cheng
  • Debra Scarlata
  • Karl Swedberg
  • James B. Young
  • M. Amuchastegui
  • C. Belziti
  • J. Bluguermann
  • M. Caccavo
  • L. Cartasegna
  • R. Colque
  • C. Cuneo
  • A. Fernandez
  • A. Gabito
  • R. Goicochea
  • M. Gonzalez
  • V. Gorosito
  • L. Grinfeld
  • M. Hominal
  • R. Kevorkian
  • M. Litvak Bruno
  • J. Llanos
  • I. Mackinnon
  • O. Manuale
  • E. Marzetti
  • D. Nul
  • E. Perna
  • M. Riccitelli
  • A. Sanchez
  • D. Santos
  • P. Schygiel
  • J. Toblli
  • D. Vogel
  • A. Aggarwal
  • J. Amerena
  • F. De Looze
  • P. Fletcher
  • D. Hare
  • M. Ireland
  • H. Krum
  • J. Lattimore
  • T. Marwick
  • A. Sindone
  • P. Thompson
  • J. Waites
  • J. Altenberger
  • C. Ebner
  • K. Lenz
  • R. Pacher
  • G. Poelzl
  • F. Charlier
  • M. de Ceuninck
  • G. De Keulenaer
  • P. Dendale
  • P. Maréchal
  • W. Mullens
  • J. Thoeng
  • M. Vanderheyden
  • J. Vanhaecke
  • C. Weytjens
  • B. Wollaert
  • D. Albuquerque
  • D. Almeida
  • J. Aspe y Rosas
  • E. Bocchi
  • S. Bordignon
  • N. Clausell
  • S. Kaiser
  • P. Leaes
  • S. Martins Alves
  • M. Montera
  • L. Moura
  • R. Pereira de Castro
  • S. Rassi
  • A. Reis
  • J. Saraiva
  • M. Simões
  • J. Souza Neto
  • M. Teixeira
  • H. Benov
  • B. Chompalova
  • T. Donova
  • P. Georgiev
  • D. Gotchev
  • A. Goudev
  • M. Grigorov
  • D. Guenova
  • V. Hergeldjieva
  • D. Ivanov
  • E. Kostova
  • A. Manolova
  • S. Marchev
  • F. Nikolov
  • A. Popov
  • D. Raev
  • M. Tzekova
  • W. Czarnecki
  • N. Giannetti
  • H. Haddad
  • J. Heath
  • T. Huynh
  • S. Lepage
  • P. Liu
  • E. Lonn
  • P. Ma
  • D. Manyari
  • G. Moe
  • J. Parker
  • Y. Pesant
  • M. Rajda
  • J. Ricci
  • S. Roth
  • F. Sestier
  • V. Sluzar
  • B. Sussex
  • S. Vizel
  • G. Antezana
  • C. Bugueno
  • P. Castro
  • C. Conejeros
  • L. Manriquez
  • D. Martinez
  • S. Potthoff
  • B. Stockins
  • J. Vukasovic
  • P. Gregor
  • M. Herold
  • O. Jerabek
  • R. Jirmar
  • R. Kuchar
  • A. Linhart
  • B. Podzemska
  • M. Soucek
  • J. Spac
  • R. Spacek
  • P. Vodnansky
  • J. Bronnum-Schou
  • K. Clemmensen
  • K. Egstrup
  • G. Jensen
  • L. Kjoller-Hansen
  • L. Kober
  • J. Markenvard
  • J. Rokkedal
  • K. Skagen
  • C. Torp-Pedersen
  • C. Tuxen
  • L. Videbak
  • T. Laks
  • V. Vahula
  • V. Harjola
  • R. Kettunen
  • M. Kotila
  • F. Bauer
  • A. Cohen Solal
  • D. Coisne
  • J. Davy
  • P. De Groote
  • P. Dos Santos
  • F. Funck
  • M. Galinier
  • P. Gibelin
  • R. Isnard
  • Y. Neuder
  • G. Roul
  • R. Sabatier
  • J. Trochu
  • S. Anker
  • S. Denny
  • T. Dreykluft
  • M. Flesch
  • S. Genth-Zotz
  • R. Hambrecht
  • J. Hein
  • M. Jeserich
  • M. John
  • H. Kreider-Stempfle
  • U. Laufs
  • K. Muellerleile
  • M. Natour
  • M. Sandri
  • T. Schäufele
  • E. von Hodenberg
  • K. Weyland
  • B. Winkelmann
  • H. Tse
  • B. Yan
  • B. Barsi
  • J. Csikasz
  • C. Dezsi
  • I. Edes
  • T. Forster
  • P. Karpati
  • C. Kerekes
  • E. Kis
  • I. Kosa
  • G. Lupkovics
  • A. Nagy
  • I. Preda
  • A. Ronaszeki
  • J. Tomcsanyi
  • K. Zamolyi
  • D. Agarwal
  • V. Bahl
  • A. Bordoloi
  • K. Chockalingam
  • M. Chopda
  • V. Chopra
  • J. Dugal
  • N. Ghaisas
  • S. Ghosh
  • P. Grant
  • S. Hiremath
  • S. Iyengar
  • B. Jagadeesa Subramania
  • P. Jain
  • A. Joshi
  • A. Khan
  • A. Mullasari
  • S. Naik
  • A. Oomman
  • V. Pai
  • R. Pareppally Gopal
  • K. Parikh
  • T. Patel
  • V. Prakash
  • B. Sastry
  • S. Sathe
  • N. Sinha
  • V. Srikanthan
  • P. Subburamakrishnan
  • H. Thacker
  • G. Wander
  • D. Admon
  • A. Katz
  • E. Klainman
  • B. Lewis
  • A. Marmor
  • M. Moriel
  • M. Mosseri
  • A. Shotan
  • J. Weinstein
  • R. Zimlichman
  • P. Agostoni
  • M. Albanese
  • G. Alunni
  • R. Bini
  • A. Boccanelli
  • L. Bolognese
  • C. Campana
  • E. Carbonieri
  • C. Carpino
  • L. Checco
  • F. Cosmi
  • G. D'Angelo
  • M. De Cristofaro
  • A. Floresta
  • A. Fucili
  • M. Galvani
  • A. Ivleva
  • S. Marra
  • G. Musca
  • N. Peccerillo
  • P. Perrone Filardi
  • E. Picchio
  • T. Russo
  • L. Scelsi
  • M. Senni
  • L. Tavazzi
  • A. Erglis
  • I. Jasinkevica
  • N. Kakurina
  • I. Veze
  • E. Volans
  • A. Bagdonas
  • E. Berukstis
  • J. Celutkiene
  • A. Dambrauskaite
  • D. Jarasuniene
  • D. Luksiene
  • A. Rudys
  • G. Sakalyte
  • S. Sliaziene
  • R. Aguilar-Romero
  • E. Cardona-Muñoz
  • J. Castro-Jimenez
  • J. Chavez-Herrera
  • E. Chuquiure Valenzuela
  • G. De la Pena
  • E. Herrera
  • J. Leiva-Pons
  • A. Lopez Alvarado
  • G. Mendez Machado
  • G. Ramos-Lopez
  • D. Basart
  • E. Buijs
  • J. Cornel
  • M. de Leeuw
  • R. Dijkgraaf
  • P. Dunselman
  • M. Freericks
  • K. Hamraoui
  • T. Lenderlink
  • G. Linssen
  • P. Lodewick
  • C. Lodewijks
  • D. Lok
  • P. Nierop
  • E. Ronner
  • A. Somsen
  • J. van Dantzig
  • P. van der Burgh
  • L. van Kempen
  • B. van Vlies
  • A. Voors
  • A. Wardeh
  • F. Willems
  • K. Dickstein
  • T. Gundersen
  • T. Hole
  • J. Thalamus
  • A. Westheim
  • M. Dabrowski
  • J. Gorski
  • J. Korewicki
  • K. Kuc
  • P. Miekus
  • W. Musial
  • J. Niegowska
  • W. Piotrowski
  • P. Podolec
  • L. Polonski
  • P. Ponikowski
  • A. Rynkiewicz
  • R. Szelemej
  • M. Trusz-Gluza
  • M. Ujda
  • D Wojciechowski
  • A. Wysokinski
  • A. Camacho
  • C. Fonseca
  • P. Monteiro
  • E. Apetrei
  • I. Bruckner
  • E. Carasca
  • I. Coman
  • M. Datcu
  • S. Dragulescu
  • P. Ionescu
  • D. Iordachescu-Petica
  • I. Manitiu
  • V. Popa
  • A. Pop-Moldovan
  • M. Radoi
  • S. Stamate
  • M. Tomescu
  • I. Vita
  • G. Aroutiounov
  • M. Ballyuzek
  • B. Bart
  • S. Churina
  • M. Glezer
  • B. Goloshchekin
  • Z. Kobalava
  • V. Kostenko
  • Y. Lopatin
  • A. Martynov
  • V. Orlov
  • E. Semernin
  • Z. Shogenov
  • B. Sidorenko
  • A. Skvortsov
  • G. Storzhakov
  • V. Sulimov
  • O. Talibov
  • S. Tereshenko
  • V. Tsyrline
  • V. Zadionchenko
  • D. Zateyshchikov
  • A. Dzupina
  • M. Hranai
  • J. Kmec
  • K. Micko
  • J. Murin
  • D. Pella
  • G. Sojka
  • V. Spisak
  • P. Vahala
  • D. Vinanska
  • A. Badat
  • J. Bayat
  • S. Dawood
  • E. Delport
  • G. Ellis
  • R. Garda
  • E. Klug
  • T. Mabin
  • D. Naidoo
  • M. Pretorius
  • N. Ranjith
  • L. Van Zyl
  • H. Weich
  • M. Anguita
  • J. Berrazueta
  • J. Bruguera i Cortada
  • E. de Teresa
  • M. Gómez Sánchez
  • J. González Juanatey
  • I. Gonzalez-Maqueda
  • R. Jordana
  • J. Lupon
  • L. Manzano
  • D. Pascual Figal
  • L. Pulpón
  • J. Recio
  • F. Ridocci Soriano
  • J. Rodríguez Lambert
  • E. Roig Minguell
  • J. Romero
  • P. Valdovinos
  • L. Klintberg
  • T. Kronvall
  • M. Lycksell
  • S. Morner
  • E. Rydberg
  • K. Swedberg
  • I. Timberg
  • G. Wikstrom
  • T.4 Moccetti
  • J. Ashok
  • P. Banerjee
  • G. Carr-White
  • J. Cleland
  • E. Connolly
  • M. Francis
  • R. Greenbaum
  • H. Kadr
  • S. Lindsay
  • J. McMurray
  • S. Megarry
  • A. Memon
  • D. Murdoch
  • R. Senior
  • I. Squire
  • L. Tan
  • K. Witte
  • K. Adams
  • P. Adamson
  • A. Adler
  • L. Altschul
  • A. Altschuller
  • H. Amirani
  • I. Anand
  • C. Andreou
  • M. Ansari
  • M. Antonishen
  • H. Banchs
  • S. Banerjee
  • D. Banish
  • A. Bank
  • A. Barbagelata
  • D. Barnard
  • R. Bellinger
  • A. Benn
  • M. Berk
  • B. Berry
  • V. Bethala
  • S. Bilazarian
  • J. Bisognano
  • F. Bleyer
  • M. Blum
  • J. Boehmer
  • A. Bouchard
  • A. Boyle
  • B. Bozkurt
  • C. Brown
  • B. Burlew
  • K. Burnham
  • J. Butler
  • J. Call
  • P. Cambier
  • T. Cappola
  • R. Carlson
  • B. Chandler
  • R. Chandra
  • P. Chandraratna
  • R. Chernick
  • D. Colan
  • H. Colfer
  • W. Colucci
  • T. Connelly
چکیده

AIMS This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. METHODS AND RESULTS Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L. CONCLUSION The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Anemia and heart failure: Is there still a role for erythropoiesis-stimulating agents?

A early reports of erythropoiesis-stimulating agents (ESAs) having success correcting anemia in heart failure (HF), the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) study, a large phase III trial, demonstrated that darbepoetin alfa was not able to improve clinical outcomes in patients with HF who had reduced ejection fraction and mild to moderate anemia, and indeed, it led ...

متن کامل

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.

BACKGROUND Substantial evidence suggests that anemia is an independent risk factor for worse outcomes in patients with heart failure (HF). The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF. METHODS AND RESULTS Patients (N=319) with symptomatic HF, left ...

متن کامل

Erythropoietin and heart failure: the end of a promise?

For over a decade, anaemia has been explored in heart failure (HF) patients. Anaemia is observed in 25–40% of HF patients depending on the severity of disease and definition of anaemia. Furthermore, its presence is associated with increased mortality and HF hospitalizations. In patients with anaemia, mortality risk is approximately doubled. The aetiology of anaemia in HF is multifactorial, incl...

متن کامل

Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients

Patients with chronic kidney disease (CKD) have a high burden of mortality and cardiovascular morbidity. Additional strategies to modulate cardiovascular risk in this population are needed. Anaemia has been associated with adverse outcomes in CKD populations, and the ability to modify this parameter with the use of erythropoiesis-stimulating agents has been a topic of much debate. Data on the e...

متن کامل

Treatment of anemia with darbepoetin alfa in systolic heart failure.

BACKGROUND Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. METHODS In this randomized, double-blind trial, we assigned 2278 patients with systolic heart failure and mild-to-moderate anemia (hemog...

متن کامل

Right ventricular dysfunction for prognosis in haemodynamically stable patients with acute symptomatic pulmonary embolism.

treatment, the role of the renin–angiotensin system in the etiology of anaemia may be of importance. In a recent meta-analysis in which .150 000 patients were investigated, we showed that anaemia in CHF is clearly associated with an increased mortality. Therefore judicious correction of anaemia with erythropoiesis stimulating proteins (ESP) should continue to be investigated. So far, relatively...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2013